NASDAQ:AUTL
Autolus Therapeutics plc
Autolus Therapeutics plc's revenue grew 644.9% in fiscal 2025 to $75.4M while operating margin rose to −358.9%, its highest in 3 years. Free cash flow was −$302.6M, −401.4% of revenue, and the diluted share count rose 4.3%.Summary generated from Autolus Therapeutics plc's SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$75.4M
Revenue growth+644.9%
Revenue, 5-yr CAGRn/a
Gross margin−27.8%
Operating margin−358.9%
Net margin−381.4%
ROICn/a
Return on equity−95.0%
Debt / equityn/a
Free cash flow−$302.6M
FCF margin−401.4%
Share count change+4.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 2 | 10 | 75 |
| Operating income | −141 | −143 | −180 | −241 | −271 |
| Net income | −142 | −149 | −208 | −221 | −288 |
| Free cash flow | −127 | −123 | −157 | −228 | −303 |
Recent filings
- 4Insider transaction report
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KRegulation FD disclosure
Aug 3, 2026 - 8-KEntry into a material agreement
Aug 3, 2026 - 4Insider transaction report
Jul 1, 2026 - 8-KResults of a shareholder vote
Jun 29, 2026 - 8-KOther events
Jun 9, 2026